Home » Newsletters » BioWorld Science

BioWorld Science

Sep. 21, 2009

View Archived Issues

SK Chemicals to evaluate SID-530 and taxotere bioequivalence in a phase I trial

Novel MEK inhibitors in early development at UCB

New data on oseltamivir in H1N1 and H5N1 viruses discussed at ICAAC

In vitro, in vivo and phase I studies describe antibacterial ozenoxacin

Rib-X receives NIAID award to develop antibiotic treatment for gonorrhea

Arena reports BLOSSOM trial results for weight management

Vernalis completes recruitment in phase II V-3381 study for neuropathic pain

Zolinza approved in Canada for advanced cutaneous T-cell lymphoma

S1P1 receptor modulator BAF-312 developed as a potential new treatment for MS

Vitamin D3 analogue TEI-K04887 reduces PTH levels without causing hypercalcemia in vivo

MK-0674 reduces tumor-induced osteolysis in rabbit model of metastatic bone disease

OSI dislcoses novel protein kinase inhibitors for treating cancer

Neurogen describes novel TRPV1 modulators for the treatment of pain

New compounds for asthma therapy claimed by AstraZeneca and Argenta Discovery

Cel-Sci to begin clinical study of LEAPS-H1N1 in H1N1-infected patients

Hyperion receives orphan drug status for HPN-100 for hepatic encephalopathy

FDA Advisory Committee recommends Xiaflex approval for Dupuytren's disease

GSK provides update on pandemic (H1N1) influenza vaccine

Intarcia Therapeutics commences enrollment in phase II ITCA-650 study

KemPharm nominates candidate for treatment of pain

Sanofi-aventis receives FDA Complete Response Letter for eplivanserin

Savient provides update on meeting with FDA for Krystexxa

Pharmos reports results of phase IIb dextofisopam trial in irritable bowel syndrome

Biomoda adds longitudinal study to lung cancer phase II trial protocol

Companies validate cardiomyocyte progenitors derived from human embryonic stem cells

JTT-305 shows promise for the treatment of hypocalcemia and osteoporosis

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 31, 2026.
AIDS 2026: New targets for metabolic dysfunction despite ART
BioWorld
Although antiretroviral therapy (ART) can suppress HIV to undetectable levels, a growing body of evidence suggests that the virus leaves a lasting biological...
Tuojie Biotech (Shanghai) synthesizes new SARM1 inhibitors
BioWorld Science
Tuojie Biotech (Shanghai) Co. Ltd. has prepared and tested NAD(+) hydrolase SARM1 (SAMD2; MyD88-5) inhibitors found to be potentially useful for the treatment of...
Jingxin discloses new muscarinic and sigma receptor agonists
BioWorld Science
Shanghai Jingxin Biopharmaceutical Co. Ltd. and Zhejiang Jingxin Pharmaceutical Co. Ltd. have synthesized new muscarinic acetylcholine receptor and sigma receptor...
Death in Chinese gene-editing trial exposes ethical fault lines
BioWorld
The death of a 6-year-old girl after receiving an experimental brain-directed gene-editing therapy at the Xinhua Hospital in Shanghai has reopened debate over how...